U.S. Markets close in 5 hrs 28 mins

Depomed, Inc. (DEPO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.41-0.03 (-0.29%)
As of 10:32AM EDT. Market open.
People also watch
HZNPDRRXENDPAMAGCYTK

Depomed, Inc.

7999 Gateway Boulevard
Suite 300
Newark, CA 94560
United States
510-744-8000
http://www.depomedinc.com

SectorHealthcare
IndustryDrug Manufacturers - Other
Full Time Employees490

Key Executives

NameTitlePayExercisedAge
Mr. August J. Moretti J.D., Esq.CFO & Sr. VP611.34k71.74k66
Mr. Matthew M. GoslingSr. VP, Gen. Counsel & Sec.712.74kN/A46
Mr. Thadd M. VargasSr. VP of Bus. Devel.493.55k138.53k51
Dr. Srinivas G. Rao M.D., Ph.D.Chief Medical Officer & Sr. VP625.81k6.74k48
Mr. Arthur Joseph HigginsCEO, Pres & DirectorN/AN/A61
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. The company sells its products to wholesalers and retail pharmacies. It also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.

Corporate Governance

Depomed, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 2. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 2; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.